Integrating Network Pharmacology And Experimental Verification To Explore The Mechanism Of Qionggui Power Against Atherosclerosis
y. wang, y. man, x. jiang, d. shui, q. zhao, s. li, g. zhuang
Abstract
Qionggui Power (QP), a classic prescription in Traditional Chinese Medicine (TCM), has shown potential in the treatment of atherosclerosis during the past decades. However, the mechanism that mediates these cardiovascular benefits remains to be fully elucidated. Here, we investigated the effects and mechanisms of QP against atherosclerosis with network pharmacology approaches and in vitro model. The active ingredients and related targets of QP were collected from public databases. The hub targets and signaling pathways of QP against AS were defined by extensive application of bioinformatics approaches, including the protein-protein interaction (PPI) network, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG). The predicted major targets were validated in LPS-stimulated murine macrophages RAW264.7. The anti-inflammatory properties of QP were also evaluated in this model. In silico investigation of QP resulted in the identification of 18 active ingredients and 49 chemical targets intersecting with AS-related genes. And KEGG pathway analysis revealed a high enrichment in the Lipid and Atherosclerosis pathway of these chemical targets. Biochemical analysis showed marked effects of QP on the expression of predicted chemical targets (PPARr, CAT, PTGS2) and LPS-induced inflammatory genes (IL1, IL6, and TNF). And these inhibitory effects were linked to the suppression of the NF-{kappa}B signaling pathway, which was activated by the LPS stimulus. Our findings revealed the therapeutic potential of QP in the prevention and treatment of atherosclerosis. Graphical Abstract O_FIG_DISPLAY_L [Figure 1] M_FIG_DISPLAY C_FIG_DISPLAY
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Neratinib, a clinical drug against breast cancer, protects against atherosclerosis via ASK1 inhibition
Fan-shun Zhang, Chenyang He, … Suowen Xu·Circulation ResearchPeer-reviewed·Jan 9, 2026
- Anti-oxidant Response of Lipidom Modulates Lipid Metabolism in Caenorhabditis elegans and in OxLDL-Induced Human Macrophages by Tuning Inflammatory Mediators
A. Balkrishna, V. Gohel, … A. Varshney·bioRxiv·Nov 14, 2022
- Colchicine promotes atherosclerotic plaque stability independently of inflammation
- Potential Pharmacodynamic Mechanism of the Main ingredients in Licorice for Chronic Obstructive Pulmonary Disease
Cai Chen, Jianpeng An, … Yang Shen·bioRxiv·Aug 29, 2021
- A Network Pharmacology Approach to Elucidate the Anti-inflammatory Effects of Ellagic Acid
S. H. Hoang, H. Dao, E. M. Lam·bioRxiv·Jan 10, 2023
- CCL2/CCR2 inhibition in atherosclerosis: a meta-analysis of preclinical studies
L. Zivkovic, Y. Asare, … M. K. Georgakis·bioRxiv·Apr 16, 2021